Uncategorized Archives - Page 52 of 145

MondayApr 11, 2022 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo…

MondayApr 11, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors By crossing this protective barrier, Berubicin holds promise for the thousands of adult Americans diagnosed with malignant central nervous system cancers annually This year, about 25,050 adults (14,170 men and 10,880 women) will be diagnosed with malignant central nervous system (“CNS”) tumors – cancerous tumors that start in the spinal…

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

WednesdayApr 06, 2022 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions,…

TuesdayApr 05, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging. Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being. Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin…

TuesdayApr 05, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemic Mydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT markets – with potential growth across all avenues In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”)…

MondayApr 04, 2022 9:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021 At the end of 2021, CNS gained approval from swissethics to initiate trial sites in Switzerland for the global trial of Berubicin Virtual event participation can be found on the CNS website under “Events” CNS…

ThursdayMar 31, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system,…

WednesdayMar 30, 2022 9:00 am

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The company signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD Silo currently has under review four U.S.…

TuesdayMar 29, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancer CNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in June 2020 Berubicin is a novel anthracycline capable of crossing the blood-brain barrier The company received approval from Switzerland’s swissethics organization for Berubicin trials there, boosting CNS’s efforts at a global response to…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

Silo Pharma Inc. (SILO) Is ‘One to Watch’

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search